These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 2230873

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D, Mastrangelo MJ.
    Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
    Berd D, Sato T, Mastrangelo MJ.
    Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
    Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg LS, Spitler LE, Church C, O'Connor AA, Beutel LD.
    Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
    [Abstract] [Full Text] [Related]

  • 8. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G.
    J Clin Oncol; 2003 Sep 01; 21(17):3343-50. PubMed ID: 12947071
    [Abstract] [Full Text] [Related]

  • 9. M-Vax: an autologous, hapten-modified vaccine for human cancer.
    Berd D.
    Expert Rev Vaccines; 2004 Oct 01; 3(5):521-7. PubMed ID: 15485331
    [Abstract] [Full Text] [Related]

  • 10. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
    Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ.
    J Clin Oncol; 2004 Feb 01; 22(3):403-15. PubMed ID: 14691123
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
    Hsueh EC, Gupta RK, Qi K, Morton DL.
    J Clin Oncol; 1998 Sep 01; 16(9):2913-20. PubMed ID: 9738558
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide.
    Elias EG, Suter CM, Fabian DS.
    J Surg Oncol; 1997 Jan 01; 64(1):17-22. PubMed ID: 9040795
    [Abstract] [Full Text] [Related]

  • 19. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
    Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL.
    J Clin Oncol; 2002 Dec 01; 20(23):4549-54. PubMed ID: 12454111
    [Abstract] [Full Text] [Related]

  • 20. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
    Berd D, Maguire HC, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ.
    J Clin Oncol; 1997 Jun 01; 15(6):2359-70. PubMed ID: 9196151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.